Navigation Links
Pro-Dex, Inc. Announces Fiscal Second Quarter And Six-Month Results
Date:1/10/2013

other costs associated with the contested election of directors, without which such costs the reduction in operating expenses would have been 12%.

Loss from continuing operations for the quarter ended December 31, 2012 was $364,000, compared to a loss from continuing operations of $329,000 in the corresponding quarter in 2011.  Net loss for the quarter ended December 31, 2012 was $348,000, or $0.11 per diluted share, compared to a net loss of $292,000, or $0.09 per diluted share, for the corresponding quarter in 2011.  Earnings before interest, income taxes and depreciation ("EBITDA") for the quarter ended December 31, 2012 was a loss of $196,000, compared to a loss of $130,000 in the corresponding quarter in 2011.

During the quarter ended December 31, 2012, the Company used $619,000 of cash in operating activities.  This use of cash reflects primarily payments made in the second fiscal quarter for the build-up of inventory in first fiscal quarter in anticipation of customer orders and pursuant to the Company's operating plan, one of the foundational objectives of which is to reduce production lead times.

Six Months Ended December 31, 2012Sales for the six months ended December 31, 2012 decreased 29% to $6.5 million from $9.1 million in the corresponding six-month period in 2011.  Excluding sales to the Company's former largest customer, which represented a reduction of $3.8 million in the six months ended December 31, 2012 from the corresponding period in 2011, sales for the six months ended December 31, 2012 increased $1.2 million, or 25%, in the six months ended December 31, 2012. During the six months ended December 31, 2012, the Company received new orders of $9.4 million, compared to $2.8 million in the corresponding period in 2011, excluding orders received from the former largest customer.  The book to bill ratio for the six months ended December 31, 2012 was 1.5.

For the six months ended December 31, 20
'/>"/>

SOURCE Pro-Dex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Pro-Dex, Inc. Announces Fiscal 2013 First Quarter Results
2. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter And Full-Year Results
3. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
4. Pro-Dex, Inc. Announces Update Conference Call and Webcast
5. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
6. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
7. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
8. Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
9. Accelr8 Announces Results of 2012 Annual Meeting
10. OncoSec Medical Announces $7.2 Million Public Offering
11. Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013   ... announced today the publication of study results involving ... CyberKnife® Robotic Radiosurgery System, the most widely used ... The study followed 304 patients for a median ... post-treatment and found that 97 percent of patients ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, Inc. ... analysis of its double-blind, randomized, controlled Phase 2b ... gene therapy product designed to deliver the neurotrophic ... identified a more robust response to CERE-120 in ... treatment relative to those diagnosed 10 years or ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... drugs that target key enzymes in tumor cells have ... from spending long hours at infusion centers to receive ... patients using these oral medications are also on other ... benefit from their cancer treatment, or increase the risk ...
... MESA, Ariz., March 16, 2012 /PRNewswire/ -- On ... filed a collective action lawsuit against Sunovion Pharmaceuticals for failure ... are entitled under the Fair Labor Standards Act (FLSA). The Complaint ... District of Oregon on behalf of all Sunovion pharmaceutical reps ...
Cached Medicine Technology:Medco Study Finds Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions 2Medco Study Finds Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions 3Medco Study Finds Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions 4JacksonWhite Files Overtime Lawsuit Against Sunovion Pharmaceuticals 2
(Date:5/21/2013)... Beginning May 21st, 2013, DTP Sales ... 8000, the newest in digital recording technology, to the ... product for anyone looking to get the most from ... 8000 is expected to have revolutionary options and ... voice recorder features and highlights: , ...
(Date:5/21/2013)... 2013 Tools4ever, the market leader in ... Self Service Reset Password Management (SSRPM) suitable for BYOD. ... use the service on mobile systems i.e.; laptops, tablets, ... easily reset their Windows passwords anywhere, anytime. Once the ... the user may then reset his or her own ...
(Date:5/21/2013)... By Alan Mozes HealthDay Reporter , , ... medications used by millions of people with chronic ... of cardiovascular complications among older patients, a new ... around patients over age 65 who are prescribed ... or beta-agonists (such as Serevent). Both medications are ...
(Date:5/21/2013)... 2013, PHILADELPHIA The surgical management of non-small cell ... on the race of the patient, according to a ... Stage I and Stage II NSCLC is surgery," said ... Center in Omaha, Nebraska. "In our study of more ... between the years 2000 and 2010, we found statistically ...
(Date:5/21/2013)... ATS 2013, PHILADELPHIA ─ A novel approach to ... types of asthma has shown promise in a ... researchers. , Their research will be presented at ... published simultaneously online in the New England ... placebo-controlled trial tested the efficacy and safety of ...
Breaking Medicine News(10 mins):Health News:DTP Sales & Service Announces Upcoming Availability Of Philips Pocket Memo 8000 Series 2Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3
... San Diego, September 12, 2011 - The Journal of ... a special 150-page four-volume digital issue featuring first-person accounts ... the morning of September 11, 2001, when terrorists invaded ... changed the way they, and most responders throughout the ...
... 12 (HealthDay News) -- Linking doctors, offices with pharmacies ... who follow doctor,s orders on medications for chronic illnesses, ... more than 12,00 men and women who were given ... over a period of 18 months. All of ...
... certain hereditary cancers develop them at earlier ages than women ... , a peer-reviewed journal of the American Cancer Society, the ... cancer diagnosis to determine when to provide counseling, screening, and ... BRCA genes have a high risk of developing breast and ...
... of the most deadly and common types of brain tumor, ... seizures and effective treatments for them have been elusive. ... has found that human gliomas implanted in mice release excess ... tumor and triggering seizures. The researchers also found that ...
... 10 (HealthDay News) -- Many U.S. college students aren,t getting ... a problem that could affect their ability to learn, a ... 200 undergraduate college students aged 18 to 24 who did ... them worked full- or part-time, and only 24 percent said ...
... in Latin America to take urgent action against preventable strokes ... year, AF increases the risk of stroke fivefold and is ... by a blood clot blocking a blood vessel in the ... from AF , In Brazil, there are around 1.5 ...
Cached Medicine News:Health News:Out of the darkness 2Health News:Linking Pharmacies With Doctors' Offices Can Improve Med Adherence: Study 2Health News:Women who inherit BRCA gene mutations develop cancer earlier than their ancestors 2Health News:NIH-funded research points to potential therapy for tumor-associated epilepsy 2Health News:NIH-funded research points to potential therapy for tumor-associated epilepsy 3Health News:Medical and patient communities call for urgent action to prevent stroke crisis in Latin America 2Health News:Medical and patient communities call for urgent action to prevent stroke crisis in Latin America 3Health News:Medical and patient communities call for urgent action to prevent stroke crisis in Latin America 4
... available in four standard sizes. They offer ... to expensive, reusable brain biopsy needles. In ... Guide offers a simple yet secure method ... of our biopsy needles, using frameless stereotactic, ...
A complete system of cannulas, needles and rasps specifically designed for inside-out meniscal repair procedures....
... Flexible Digital Implant offers surgeons an alternative ... correction of a hammertoe deformity. The prosthesis ... and is designed for the proximal interphalangeal ... Futura FDI features an anatomic hinge design ...
... Therapy has been approved for use as ... of seizures in adults and adolescents over ... seizures that are refractory to antiepileptic medications. ... 5 controlled, clinical trials. Efficacy, measured as ...
Medicine Products: